Hot COVID-19
Home > News > AMSBIO: A New iPSC Model for COVID-19
Industry Updates New Products Supplier News Upcoming Events business web

AMSBIO: A New iPSC Model for COVID-19

Hits:234   Date: 6/18/2021
AMSBIO invite the global research community to the 2021 annual meeting of the ISSCR, the leading professional organization of stem cell scientists, to discover how iPSCs and organoids can be used in COVID-19 drug discovery research.

At this virtual meeting - Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University will be giving a unique insight into his recent pioneering research that has successfully modelled the SARS-CoV-2 life cycle in undifferentiated iPSCs, which were previously uninfectable. This innovation showcase presentation at ISCCR 2021 is sponsored by AMSBIO in association with the manufacturers Stemfit® cell culture media, iMatrix™ recombinant laminin extracellular matrix and STEMCELLBANKER® cryopreservation solutions.

 

Control (left) and SARS-CoV-2 infected (right) ACE2-iPS cells. Cells stained red for pluripotency marker and green for SARS-Cov-2 NP using Rabbit Polyclonal Anti-SARS-CoV-2 Antibody (right). 

 
It has been widely reported that genetic differences are a primary reason for differences in the susceptibility and severity of COVID-19. As induced pluripotent stem (iPS) cells maintain the genetic information of the donor, they can be used to model individual differences in SARS-CoV-2 infection in vitro. The CiRA team headed by Dr Takayama report on results demonstrating that human iPS cells expressing the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) (ACE2-iPS cells) can be infected with SARS-CoV-2. Further data is shown illustrating how SARS-CoV-2 life cycle can be reproduced in the ACE2-iPS cells, how COVID-19 candidate drugs can be evaluated using ACE2-iPS cells and how ACE2-iPS cells can reproduce individual differences in SARS-CoV-2 infection.

Dr Takayama commented: “Since we used eight ACE2-iPS cell lines in this study, we used a very large volume of Stemfit® medium and iMatrix ECM. Although many cells are required for COVID-19 drug evaluation, iPS cells cultured with Stemfit® and iMatrix™ have a high replication capacity, so that sufficient cell numbers can easily be prepared and can easily be cryopreserved as required using STEM-CELLBANKER®.”


Dr Kazuo Takayama

 
Stemfit® is the leading feeder-free medium for ES/iPS cell culture that combines superior expansion rates with lower media usage. iMatrix™ Recombinant Laminin-511 is a high -performance cell culture matrix, compatible with a wide range of cell types that is particularly well suited to iPSCs. iMatrix-511 provides a speedy non-coating protocol and offers superior cell binding compared to multiple other cell culture substrates. STEM-CELLBANKER® is a chemically defined, animal-free GMP-grade cryopreservation media, optimized for ES/iPS cells. STEM-CELLBANKER® maintains cell pluripotency, normal karyotype, and proliferation post thaw whilst also providing consistent high cell viability. All these products are available and supported internationally by AMSBIO.

To register for the live event please visit https://www.isscr.org/meetings-events/annual-meetings/isscr-annual-meeting-2021. For further information on Stemfit®, iMatrix™ Recombinant Laminin-511 and STEM-CELLBANKER® and to watch the on-demand version of this presentation after the event, please visit https://www.amsbio.com/news/an-ipsc-model-for-covid-19/ or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

Worldwide HQ

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com
Web: www.amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com
Web www.amsbio.com
AMSBIO
Tel:+44 (0) 1235 828 200
E-mail:info@amsbio.com
advertisement